NCT06654050 2026-03-17
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
Clinical Trials
10 trialsNCT06840834 2026-03-16
Bi-MAPS
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Recruiting
NCT03074513 2026-03-11
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01843374 2026-03-05
Tremelimumab
MedImmune LLC
Phase 2 Active not recruiting
NCT05960773 2026-03-04
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 2 Suspended
NCT07234058 2026-02-11
LAG-MAPS
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Not yet recruiting
NCT02662504 2026-02-05
MesoPDT
University Hospital, Lille
Phase 2 Completed
NCT05136677 2026-01-23
CheckMate 6DW
Bristol-Myers Squibb
Phase 2 Completed
NCT05380713 2025-12-29
......SMARTEST Trial......
University Health Network, Toronto
Phase 2 Completed
NCT05005429 2025-12-23
BIMES
Fundación GECP
Phase 2 Completed